Login to Your Account

Biogen Misses EPS, Exceeds Revenue; BG-12 Launch Next

By Jennifer Boggs
Managing Editor

Tuesday, January 29, 2013
Biogen Idec Inc.'s fourth-quarter earnings missed estimates, but Wall Street barely noticed as revenue topped expectations, driven largely by steady growth in multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), with investors already looking ahead to the much-anticipated launch of oral MS drug BG-12.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription